UG Healthcare narrows net loss by 70.8% in FY24

EPS stood at $0.17

UG Healthcare narrowed its net loss attributable to shareholders by 70.8% year-on-year (YoY), from $20.7m in 2023 to $6.1m this year.

This is due to markets continuing to determine a new equilibrium and average selling price of disposable examination gloves along with increase in ancillary products.

The group’s revenue rose by $14.1m, from $101.1m in 2023 to $115.2m this year due to the overall increase in sales volume. Revenue of nitrile examination gloves and other ancillary products increased by 53% YoY and 98.7% YoY respectively, whilst latex examination gloves revenue decreased by 10.7% YoY.

Share of losses profits from associates decreased to $0.1m due to losses by its German and USA associates in the first half of the year.

Basic earnings per share stood at $0.17 compared to last year’s $2.56.

Follow the link for more news on

UG Healthcare

Financial Statements

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia